CClinicalTrials.gg
RecruitingNCT06880094CARTOFENTEUpdated Jan 16, 2026

Study of Congenital Orofacial Clefts by Implementing Optical Genome Mapping

An interventional study of blood withdrawal in Orofacial Clefts, Next Generation Sequencing (NGS) and Optical Genome Mapping, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Sex
All
01

Study summary

Orofacial clefts, the most common congenital craniofacial malformations, have a complex etiology involving an interaction between genetic and environmental factors.

Chromosomal abnormalities, including structural variations, represent a major cause of human pathology. Recently, technological developments and the introduction of next-generation sequencing (NGS) technologies have revolutionized the field of medical genetics.

Optical genome mapping (OGM) is an innovative, high-resolution "long read" technique that enables the identification of all classes of chromosomal variation, consisting in the direct visualization of long, labeled DNA molecules throughout the genome. This technology is gradually becoming an essential tool for studying onco-hematology and constitutional genetic pathologies The purpose of this study is to search for structural chromosomal variants (SV) or copy number variants (CNV) not identifiable either by cytogenetic methods nor by "short read" NGS "short read, in individuals with oral-facial clefts with no genetic diagnosis.

02

Conditions studied

  • Orofacial Clefts
  • Next Generation Sequencing (NGS)
  • Optical Genome Mapping

Keywords

  • orofacial clefts
  • Next Generation Sequencing
  • Optical Genome Mapping
03

In context

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 576 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Individuals with syndromic, complex or familial oral-facial clefts
  • With no established genetic diagnosis
  • Followed up at the Amiens-Picardie University Hospital

Exclusion criteria

Exclusion Criteria:

  • genetic diagnosis of oral-facial cleft
  • No health insurance affiliation
  • Patient under guardianship or curatorship, under safeguard of justice or deprived under public law
  • Pregnant, parturient or breast-feeding woman
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    patients with syndromic, familial or complex orofacial clefts

    Genetic: blood withdrawal

Interventions

  • Geneticblood withdrawal

    blood withdrawal for genetic testing

06

What researchers measure

Primary outcomes

  1. Identification of a structural chromosomal variant

    Identification of a structural chromosomal variant involved in the genesis of orofacial clefts by studying the genetic characteristics of individuals with orofacial clefts.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • CHRU Amiens
    Amiens, 80480, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06880094
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Feb 18, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jan 16, 2026

Study contacts

Bénédicte DEMEER, MD
Contact
Demeer.Benedicte@chu-amiens.fr
33+322087581

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion